Is Viatris (VTRS) Cheap On Its Japan WAKIX Approval?

Viatris (VTRS) just picked up a fresh regulatory win in Japan, where authorities approved WAKIX for excessive daytime sleepiness tied to obstructive sleep apnea and narcolepsy, highlighting a focused push into sleep disorders.

That backdrop has coincided with a strong run for Viatris, with the 1-day share price return of 2.35% and 30-day share price return of 9.12% feeding into a 43.10% year-to-date share price return and a 93.93% total shareholder return over the past year. This points to momentum building as investors reassess both growth prospects and perceived risk around the stock.

Scan how Viatris’ sleep-disorder momentum compares with other healthcare plays by exploring 16 high quality undiscovered gems that are still flying under most investors' radar.

Bulls point to Viatris’ sleep portfolio win and its deep branded and generic lineup. Bears flag the recent share price surge and ongoing net loss. Which side does the valuation actually support next?

Most Popular Narrative: 4% Undervalued

Viatris closed at $17.83 against a widely followed fair value estimate of $18.50. This frames the recent rally as still modestly discounted rather than stretched.

The company is described as well-positioned to benefit from sustained demand growth due to global population aging and increasing chronic disease prevalence, supported by positive late-stage pipeline developments in chronic disease, pain, and ophthalmology. These factors are cited as setting the stage for long-term revenue growth through new branded and generic launches in large, underserved markets.

See why 46 investors see Viatris as 4% undervalued.

Result: Fair Value of $18.50 (UNDERVALUED)

Still, Viatris faces pressure from ongoing price erosion in key markets and heavy reliance on mature off patent products, which could challenge that undervalued narrative.

Find out about the key risks to this Viatris narrative.

Next Steps

With Viatris pulling in mixed reactions, use the numbers to stress test your own thesis and see how risks compare with potential rewards through 3 key rewards and 1 important warning sign.

Looking for more Viatris-sized investment ideas?

Do not stop at Viatris. Broaden your opportunity set with focused stock lists that surface financially driven ideas before they hit everyone else’s radar.

• Target stronger potential value by scanning companies that combine quality fundamentals with discounted pricing through 32 high quality undervalued stocks.
• Prioritise staying power and balance sheet resilience with a curated list of solid balance sheet and fundamentals (24 results) that helps you sidestep fragile businesses.
• Reduce portfolio shocks by zeroing in on companies flagged for stability using a 30 resilient stocks with low risk scores that keeps risk front and centre.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com